Assess whether the primary endpoint will survive FDA scrutiny (d358f4)

SITUATION An RWE group proposing a post-marketing study instead of a new RCT has 505(b)(2) literature-to-product bridge table in hand following a site-change that invalidates stability claims. Labeling negotiator must determine whether the primary endpoint will survive FDA scrutiny for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. The population in 505(b)(2) literature-to-product bridge table is the one a site-change that invalidates stability claims named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in 505(b)(2) literature-to-product bridge table is adjacent only to a site-change that invalidates stability claims; Pause the pathway is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained a site-change that invalidates stability claims before 505(b)(2) literature-to-product bridge table arrived; no new Clinical and Evidence Strategy path. 4. Provenance on 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a site-change that invalidates stability claims and write the one fact that would move the primary endpoint will for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for labeling negotiator - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT